MedTrace Logo

Januvia Re-examination Study (MK-0431-181)

NCT01062048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3483

Last updated 2016-02-05

No results posted yet for this study

Summary

The objectives of this survey are: 1) To examine the safety/efficacy profile of Januvia in Korean participants, and 2) To identify factors that might have an influence on the safety and efficacy profile of Januvia in Korean participants.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Conditions

Interventions

DRUG

Sitagliptin

Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label

DRUG

Sulfonylurea

Sulfonylurea administered in general use according to the local label

BIOLOGICAL

Insulin

Insulin administered in general use according to the local label

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-07-31
Completion
2013-07-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062048 on ClinicalTrials.gov